Literature DB >> 3688650

Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII.

S Idell1, K Gonzalez, H Bradford, C K MacArthur, A M Fein, R J Maunder, J G Garcia, D E Griffith, J Weiland, T R Martin.   

Abstract

Alveolar fibrin deposition commonly occurs in the lungs of patients with the adult respiratory distress syndrome (ARDS). Bronchoalveolar lavage (BAL) from patients with ARDS, control patients with interstitial lung disease (ILD), congestive heart failure, or exposure to hyperoxia, and normal healthy subjects was studied to determine whether local alterations in procoagulant activity favor alveolar fibrin deposition in the lungs in ARDS. Procoagulant activity capable of shortening the recalcification time of plasma deficient in either factor VII or factor VIII was observed in unconcentrated BAL of all patients, but was significantly greater in BAL from patients with ARDS when compared with that of control subjects (p less than 0.001). Unconcentrated BAL from patients with ARDS shortened the recalcification time of plasma deficient in factor X, but no functional thrombin was detectable. BAL procoagulant from patients with ARDS was inhibited by concanavalin A, an inhibitor of tissue factor. The hydrolysis of purified human factor X by BAL from the ARDS and other patient groups was determined by measuring the amidolytic activity of generated factor Xa on its N-benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroanilide substrate. The procoagulant activity of BAL was associated with the development of amidolytic activity, indicating activation of factor X. BAL from patients with ARDS contained more factor X activating activity than did BAL from control groups (p less than 0.001). This activity was calcium dependent and was maximal at 1 mM ionized calcium. The BAL factor X activating activity was most active at neutral pH and was sedimented by ultracentrifugation at 100,000 x g.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3688650     DOI: 10.1164/ajrccm/136.6.1466

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  39 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.

Authors:  Jean-Christophe Richard; Fabienne Bregeon; Véronique Leray; Didier Le Bars; Nicolas Costes; Christian Tourvieille; Franck Lavenne; Mojgan Devouassoux-Shisheboran; Gerard Gimenez; Claude Guerin
Journal:  Intensive Care Med       Date:  2007-08-02       Impact factor: 17.440

3.  Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury.

Authors:  Marcus J Schultz; Marcel Levi
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

4.  Development of animal models for the acute respiratory distress syndrome.

Authors:  Julie A Bastarache; Timothy S Blackwell
Journal:  Dis Model Mech       Date:  2009 May-Jun       Impact factor: 5.758

5.  Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns.

Authors:  S Peyrol; J F Cordier; J A Grimaud
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

6.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage.

Authors:  S Idell; J Peters; K K James; D S Fair; J J Coalson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 8.  Anticoagulant therapy in acute respiratory distress syndrome.

Authors:  Marta Camprubí-Rimblas; Neus Tantinyà; Josep Bringué; Raquel Guillamat-Prats; Antonio Artigas
Journal:  Ann Transl Med       Date:  2018-01

9.  Procoagulant and fibrinolytic activity in ventilator-associated pneumonia: impact of inadequate antimicrobial therapy.

Authors:  Ali A El-Solh; Mifue Okada; Celestino Pietrantoni; Alan Aquilina; Eileen Berbary
Journal:  Intensive Care Med       Date:  2004-07-23       Impact factor: 17.440

10.  Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome.

Authors:  Julie A Bastarache; Richard D Fremont; Jonathan A Kropski; Frederick R Bossert; Lorraine B Ware
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-21       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.